Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2025 / July / Spectral Cytometry Enhances CAR T Monitoring
Pharma and Biopharma

Spectral Cytometry Enhances CAR T Monitoring

A new spectral flow cytometry workflow could shape CAR T product quality and therapeutic outcomes

By Stephanie Vine 07/04/2025 2 min read

Share

0625-106-Characterizing-CAR-T-cells_Teaser.png

Researchers at the Keck School of Medicine of USC have developed a new analytical method to more precisely characterize CAR T cells during manufacturing. Using spectral flow cytometry and multiparametric analysis, the team profiled the phenotypic and functional evolution of CAR T cells during a five-day expansion period.

CAR T cell therapies involve genetically engineering a patient's T cells to express a chimeric antigen receptor (CAR), enabling the cells to recognize and kill tumor cells. However, the manufacturing process can introduce considerable variability in the final cell product. The researchers wanted to better understand how CAR T cells change during ex vivo expansion and how those changes might influence therapeutic outcomes.

“Just as every person has a fingerprint that identifies them, T cells also have fingerprints. By measuring the expression of markers on a cell’s surface, we can learn more about what distinguishes one CAR T cell therapy from another,” said senior study author Mohamed Abou-el-Enein.

The researchers observed that five-day expansion led to increased proportions of T cell subsets associated with central memory and stem cell memory phenotypes subsets – which are also thought to support more durable anti-tumor responses. At the same time, expression of proinflammatory cytokines and markers linked to effector differentiation and exhaustion were reduced, potentially indicating a more favorable therapeutic profile.

To conduct the analysis, the team developed a high-dimensional spectral flow cytometry panel encompassing over 30 surface and intracellular markers, enabling single-cell resolution of phenotypic and functional changes. The approach showed that CAR T cells maintain plasticity during the early phase of expansion, with key transcriptional regulators and cytokine profiles shifting significantly over time. The data also suggest that certain early differentiation states may be predictive of in vivo persistence and efficacy, offering potential markers for product optimization and quality control.

“This work fills a critical gap in our understanding of how manufacturing conditions shape the therapeutic potential of CAR T cells,” said Abou-el-Enein. “By pinpointing when CAR T cells acquire – or lose – functional fitness, we can now tailor the timing of cell manufacturing, which could have an immediate impact on clinical decision-making and patient outcomes.”

Abou-el-Enein suggests that this type of detailed immunophenotyping could be integrated into CAR T manufacturing protocols to guide product selection and release criteria, and to reduce batch-to-batch variability. The workflow may also support regulatory submissions by enhancing product characterization. More broadly, the study demonstrates how high-dimensional single-cell tools can be applied to advance the manufacturing science of engineered T cell therapies.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Stephanie Vine

"Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read."

More Articles by Stephanie Vine

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.